Stay updated with breaking news from நீயூ நிதி. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
SentiAR, a pioneer in visualization technology for interventional procedures, has closed an oversubscribed $5.1 million Series A financing, which will allow the company to accelerate innovation on its groundbreaking mixed reality SentiAR is revolutionizing cardiac surgery and other interventional procedures by providing physicians with holographic visualization through mixed reality. The FDA 510(k) cleared CommandEP™ system is the first guidance system of this type to be used during invasive cardiac procedures. SentiAR CEO, Berk Tas TechWald Holding joined the round as the company s newest investor, supporting SentiAR financially and operationally. Other investors in the Series A funding include BioGenerator (the investment arm of BioSTL), Cultivation Capital, VCapital, Neue Fund, QRM Capital, and Keiretsu Forum. ....
Backers included Neue Fund, Bioventures GmbH, Lateral Capital, BeniVC, and Sky Ventures. The company, which has raised over $10M in total capital to date, intends to use the funds for digital dermatopathology development and scale of the laboratory system to extend AI research. The funds will bolster operations to facilitate larger clients and continue progress in developing innovative technology, including the extension of artificial intelligence research for various cancer lines. Led by Dan Lambert, CEO and co-founder, Pathlogywatch specializes in providing dermatology clinics with fully interfaced EMR reporting and 24/7 access to digital slides. Through these services, dermatology clinics, hospitals and laboratories can improve operational efficiency by speeding up workflow and enhancing patient outcomes by utilizing the expert professional team and partner laboratory services. The digital pathology solution includes access to top-tier dermatopathologists and a streaml ....
PathologyWatch Raises $2M in Extension Funds to Bolster Pathology AI Research Share Article Funding Led by Neue Fund and BioVentures Investors to extend AI research and allow strategic life science and AI investors into the round. Our confidence couldn’t be higher in their ingenuity and devotion to advancing the digital dermatopathology landscape. SALT LAKE CITY (PRWEB) December 16, 2020 PathologyWatch has announced $2M in extension funding from Neue Fund, Bioventures GmbH, Lateral Capital, BeniVC, and Sky Ventures. PathologyWatch will direct the capital towards digital dermatopathology development and scaling the laboratory system to extend AI research and to allow additional strategic life science and AI investors into the round. ....